Latest News on CATX

Financial News Based On Company


Advertisement
Advertisement

Form 4 Perspective Therapeutics Inc: Robert F. Williamson III (Director) For: 18 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-perspective-therapeutics-inc-robert-f-williamson-iii-director-for-18-november-93CH-5715481
This article reports a Form 4 filing for Perspective Therapeutics Inc, indicating a transaction by Director Robert F. Williamson III on November 18th. The brief notice, published by Investing.com, provides no further details about the nature or specifics of the transaction.

At $0.80 a share, the RFW3 Revocable Trust bought 15,000 shares of Perspective Therapeutics (CATX).

https://www.stocktitan.net/sec-filings/CATX/form-4-perspective-therapeutics-inc-insider-trading-activity-dc1ed76947bd.html
The RFW3 Revocable Trust, linked to Perspective Therapeutics director Robert F. Williamson III, purchased 15,000 common shares of CATX at $0.80 per share on November 18, 2026. This transaction increased the trust's holdings to 68,473 shares, with Williamson also directly holding 115,271 shares. The filing indicates a positive sentiment and is categorized as having a moderate impact.

Perspective Therapeutics director Robert Williamson buys $20,950 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/perspective-therapeutics-director-robert-williamson-buys-20950-in-stock-93CH-4967085
Robert F. Williamson III, a director at Perspective Therapeutics Inc. (NASDAQ:CATX), recently purchased 25,000 shares of the company's common stock for $20,950. The transaction occurred on November 17, 2026, with shares bought at a weighted average price of $0.838. This purchase takes place as the stock trades near its 52-week low, and InvestingPro analysis suggests it may be undervalued.

Form 4 Perspective Therapeutics Inc: Robert F. Williamson III (Director) For: 17 November

https://uk.investing.com/news/stock-market-news/form-4-perspective-therapeutics-inc-robert-f-williamson-iii-director-for-17-november-93CH-4990835
This article reports on a Form 4 filing for Perspective Therapeutics Inc., indicating a transaction by Director Robert F. Williamson III on November 17. The filing is an important disclosure for investors, offering insights into insider activity for the company (CATX).

A director’s trust bought 25,000 Perspective Therapeutics (CATX) shares at an average of $0.838 each.

https://www.stocktitan.net/sec-filings/CATX/form-4-perspective-therapeutics-inc-insider-trading-activity-ad0f666ff61e.html
The RFW3 Revocable Trust, associated with director Robert F. Williamson III of Perspective Therapeutics (CATX), purchased 25,000 shares at a weighted average price of $0.838 per share on November 17, 2026. This transaction increased the trust's holding to 53,473 shares, with Williamson directly holding an additional 115,271 shares. The purchases occurred in multiple transactions ranging from $0.8200 to $0.8500, with no Rule 10b5-1 plan reported.
Advertisement

Form 4 Perspective Therapeutics Inc: Frank Morich (Director) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-perspective-therapeutics-inc-frank-morich-director-for-16-november-93CH-5710042
This article reports on a Form 4 filing for Perspective Therapeutics Inc, indicating insider transaction activity by Frank Morich, a Director. The transaction date specified in the filing is November 16. The article primarily serves as a notice of this regulatory filing.

Perspective Therapeutics director Frank Morich buys $14,046 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/perspective-therapeutics-director-frank-morich-buys-14046-in-stock-93CH-4964167
Frank Morich, a director at Perspective Therapeutics (NASDAQ:CATX), recently purchased 15,000 shares of company stock for $14,046, at a price of $0.9364 per share. This transaction occurred on November 16, 2026, when the stock was trading near its 52-week low. InvestingPro analysis suggests the stock is undervalued, and the RSI indicates oversold conditions, potentially supporting Morich's buying decision.

Form 4 Perspective Therapeutics Inc: Frank Morich (Director) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-perspective-therapeutics-inc-frank-morich-director-for-16-november-93CH-4964185
This article reports on a Form 4 filing for Perspective Therapeutics Inc., specifically detailing a transaction involving Frank Morich, a director of the company, on November 16. The brief announcement provides no further details about the nature of the transaction.

Frank Morich buys Perspective Therapeutics (CATX) shares, taking direct holdings to 30,000.

https://www.stocktitan.net/sec-filings/CATX/form-4-perspective-therapeutics-inc-insider-trading-activity-3dd465178a03.html
Perspective Therapeutics (CATX) director Frank Morich purchased 15,000 shares of common stock on November 16, 2026, at EUR 0.85 per share, equivalent to $0.9364 per share. This transaction increased his direct holdings to 30,000 shares. The purchase was reported in a Form 4 filing accepted by the SEC on November 17, 2026, at 08:30 AM EST.

Director Frank Morich Acquires 15,000 Shares of Perspective Therapeutics at $0.9971 Each

https://kalkinemedia.com/us/news/announcements/director-frank-morich-acquires-15000-shares-of-perspective-therapeutics-at-09971-each
Director Frank Morich has purchased 15,000 shares of Perspective Therapeutics, Inc. common stock at $0.9971 per share. This transaction, disclosed in a Form 4 filing with the SEC on November 16, 2026, marks his initial direct beneficial ownership of the company's shares. The acquisition took place on November 12, 2026, and was not executed under a Rule 10b5-1(c) trading plan.
Advertisement

A pre-funded warrant accounts for the entire reported stake in Perspective Therapeutics (CATX).

https://www.stocktitan.net/sec-filings/CATX/schedule-13g-a-perspective-therapeutics-inc-amended-passive-investmen-2719c5123395.html
Commodore Capital LP, along with its managing partners, reported a 5.5% beneficial ownership stake in Perspective Therapeutics (CATX) through an amended SCHEDULE 13G/A filing. This stake, totaling 6,598,046 common shares, is entirely derived from a pre-funded warrant, subject to a 9.99% beneficial ownership limitation. The filing highlights that these shares are acquirable upon the exercise of the warrant.

A director buys 6,289 Perspective Therapeutics (CATX) shares; his trust buys 18,609.

https://www.stocktitan.net/sec-filings/CATX/form-4-perspective-therapeutics-inc-insider-trading-activity-0ecef979e52f.html
Perspective Therapeutics (CATX) director Robert F. Williamson III directly purchased 6,289 common shares on November 12, 2026, at a weighted-average price of $0.8386 per share. Additionally, the RFW3 Revocable Trust, indirectly owned by Williamson, acquired 18,609 shares on the same day at $0.8400 per share. These transactions increased Williamson's direct holdings to 115,271 shares and indirect holdings through the trust to 28,473 shares.

Director Lori A. Woods buys Perspective Therapeutics (CATX) shares at $0.8438 on average.

https://www.stocktitan.net/sec-filings/CATX/form-4-perspective-therapeutics-inc-insider-trading-activity-a95b686de1fe.html
Perspective Therapeutics, Inc. (CATX) director Lori A. Woods purchased 23,750 common shares on November 12, 2026, at a weighted-average price of $0.8438 per share. The multiple transactions ranged from $0.8437 to $0.8438, increasing her direct holdings to 28,557 shares, with an additional 183,460 shares held indirectly. This insider trade summary highlights a net purchase of 23,750 shares valued at approximately $20,000.

Perspective Therapeutics (CATX) executive Puhlmann bought 41,000 shares for $34.5K at an average $0.84

https://www.quantisnow.com/insight/chief-medical-officer-puhlmann-markus-bought-34544-worth-of-shares-6789538
Markus Puhlmann, Chief Medical Officer at Perspective Therapeutics (CATX), reported buying 41,000 shares for $34,544 at an average price of $0.84 per share. These open-market purchases, made between November 11 and November 12, 2026, increased his direct holdings by 30% to 178,542 shares. This transaction follows other insider activity, including the CEO's share purchase, and the article also provides historical stock performance after previous CATX headlines.

Form 4 Perspective Therapeutics Inc: Markus Puhlmann (Chief Medical Officer) For: 11 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-perspective-therapeutics-inc-markus-puhlmann-chief-medical-officer-for-11-november-93CH-5703223
This article reports on a Form 4 filing for Perspective Therapeutics Inc., indicating a transaction involving Markus Puhlmann, the Chief Medical Officer, on November 11th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of securities by a company's officers, directors, and principal stockholders. The article is brief and primarily serves as a notification of this insider transaction.
Advertisement

Markus Puhlmann Acquires 41,000 Shares of Perspective Therapeutics (CATX) Over Two Days

https://kalkinemedia.com/us/news/announcements/markus-puhlmann-acquires-41000-shares-of-perspective-therapeutics-catx-over-two-days
Markus Puhlmann, Chief Medical Officer at Perspective Therapeutics (CATX), purchased a total of 41,000 shares of common stock over two days, November 11 and 12, 2026. These open-market transactions increased his direct ownership to 178,542 shares. The purchases were executed at prices ranging from $0.83 to $0.8450 per share.

Perspective Therapeutics CMO Markus Puhlmann buys $34,544 in stock

https://www.investing.com/news/insider-trading-news/perspective-therapeutics-cmo-markus-puhlmann-buys-34544-in-stock-93CH-5025607
Markus Puhlmann, Chief Medical Officer at Perspective Therapeutics, recently purchased 41,000 shares of the company's common stock for a total of $34,544. These transactions occurred on November 11 and 12, 2026, with shares acquired at prices ranging from $0.83 to $0.8447. The insider buying comes as the stock trades near its 52-week low and InvestingPro analysis suggests it is undervalued and oversold.

Truist Securities maintains Perspective Therapeutics at Buy, lowers price target to $8 from $11

https://www.tradingview.com/news/tradingview:e0338e7af9286:0-truist-securities-maintains-perspective-therapeutics-at-buy-lowers-price-target-to-8-from-11/
Truist Securities has reiterated its "Buy" rating for Perspective Therapeutics (CATX) but has reduced its price target from $11 to $8, representing a 27.3% decrease. Despite the lower target, this still implies a substantial upside of 835.0% from the stock's closing price on November 9th. Other recent analyst actions on CATX include Wedbush maintaining Outperform with a $7 target and Piper Sandler maintaining Overweight with an $8 target, while RBC Capital downgraded to Sector Perform with a $4 target.

Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/63097770/perspective-therapeutics-analysts-slash-their-forecasts-after-q3-results
Perspective Therapeutics Inc (NYSE: CATX) reported a narrower Q3 loss of 27 cents per share compared to 35 cents a year ago, though sales significantly dropped to $20,000 from $209,000. Despite encouraging clinical findings, analysts from Piper Sandler and Wedbush lowered their price targets for the stock, which subsequently fell 2.4% to $0.84.

BMO reiterates Outperform on Perspective Therapeutics stock

https://www.investing.com/news/analyst-ratings/bmo-reiterates-outperform-on-perspective-therapeutics-stock-93CH-5015723
BMO Capital has reiterated an Outperform rating on Perspective Therapeutics Inc (NYSE:CATX) with an $11.00 price target, highlighting the company's third-quarter 2026 clinical program updates and an extended cash runway into 2028. Despite the stock trading down 69% year-to-date, InvestingPro analysis suggests it is undervalued at $1.15. The firm anticipates a catalyst-rich 2027, supported by the company's strong cash position relative to debt.
Advertisement

State Street shares voting power over 1.92M Perspective Therapeutics (CATX) shares.

https://www.stocktitan.net/sec-filings/CATX/schedule-13g-perspective-therapeutics-inc-passive-investment-disclosu-fece4093e083.html
State Street Corporation has reported a beneficial ownership of 2,026,991 shares, representing a 1.8% stake in Perspective Therapeutics, Inc. (CATX), as detailed in a recent SCHEDULE 13G SEC filing. The filing indicates State Street has shared voting power over 1,922,605 shares and shared dispositive power over 2,026,991 shares. The event date for this beneficial ownership report was September 30, 2026, with the document signed by Alok Maheshwary, Senior Vice President.

Wedbush lowers Perspective Therapeutics stock price target to $7

https://www.investing.com/news/analyst-ratings/wedbush-lowers-perspective-therapeutics-stock-price-target-to-7-93CH-5014686
Wedbush has lowered its price target for Perspective Therapeutics Inc (CATX) to $7.00 from $9.00, while maintaining an Outperform rating, due to adjustments in capital raise assumptions. The stock is currently trading at $0.86, having fallen significantly year-to-date and over the past six months. Despite the lowered price target, InvestingPro analysis suggests the stock may be undervalued given the company holds more cash than debt, though it is rapidly burning through cash.

Form 8K Perspective Therapeutics Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-perspective-therapeutics-inc-for-9-november-93CH-4969624
Investing.com reported on a Form 8K filing by Perspective Therapeutics Inc for November 9th. The article provides the title of the filing and specifies the company and date, indicating a regulatory disclosure of importance to investors. No further details about the content of the Form 8K are included beyond the announcement of its filing.

Perspective Therapeutics, Inc. (CATX) Misses Q3 EPS by 3c

https://www.streetinsider.com/Earnings/Perspective+Therapeutics%2C+Inc.+%28CATX%29+Misses+Q3+EPS+by+3c/27315999.html
Perspective Therapeutics, Inc. (CATX) reported a Q3 EPS of ($0.27), which was $0.03 worse than the analyst estimate of ($0.24). The company's revenue for the quarter was $20 thousand, falling short of the consensus estimate of $74.68 thousand. The article provides financial details for serious traders and links to related earnings news.

Loss per share falls to $0.27 as Q3 net loss widens at Perspective Therapeutics (CATX).

https://www.stocktitan.net/sec-filings/CATX/8-k-perspective-therapeutics-inc-reports-material-event-6405dbf8a684.html
Perspective Therapeutics (CATX) reported a wider net loss of $32.442 million in Q3 2026, compared to $25.969 million a year earlier, despite a narrower basic and diluted loss per share of $0.27 (versus $0.35). The company noted approximately $202 million in cash and equivalents, expected to fund operations into 2028, and provided updates on its clinical programs, including Fast Track Designation for PSV359.
Advertisement

CATX: Perspective Therapeutics Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/perspective-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6781768
Perspective Therapeutics Inc. reported a Q3 2026 net loss of $32.4 million, widening from $26.0 million a year prior due to increased R&D spending, but maintained a strong cash position of $202 million, projecting a runway into 2028. The company also announced that its drug candidate, PSV359, received FDA Fast Track Designation for certain FAP-positive solitary fibrous tumors.

The FDA granted Fast Track designation to Perspective’s drug for a type of fibrous tumor.

https://www.stocktitan.net/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-n4ap513c5rkq.html
Perspective Therapeutics announced a third-quarter 2026 net loss of $32.4 million, despite advancing its radiopharmaceutical clinical programs. The company's drug candidate, PSV359, received FDA Fast Track designation for adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. Perspective Therapeutics also reported approximately $202 million in liquidity, expected to fund operations into 2028, and a collaboration with Merck to evaluate PSV359 with Keytruda.

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

https://www.globenewswire.com/news-release/2026/11/09/3399027/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-3q-2026-results.html
Perspective Therapeutics, Inc. announced its third-quarter 2026 results and provided business highlights, including positive interim data for its VMT-α-NET program in neuroendocrine tumors and meningioma, and significant antitumor activity for VMT01 in metastatic melanoma. The company also reported that PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors and has a collaboration agreement with Merck. Perspective Therapeutics concluded the quarter with approximately $202 million in cash, expected to fund operations into 2028.

Form 8K Perspective Therapeutics Inc For: 6 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-perspective-therapeutics-inc-for-6-november-93CH-4965566
This article announces that Perspective Therapeutics Inc. filed a Form 8K on November 6th. The filing is categorized under stock market news.

Form 8K Perspective Therapeutics Inc For: 6 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-perspective-therapeutics-inc-for-6-november-93CH-4939889
This article announces that Perspective Therapeutics Inc. filed a Form 8K on November 6. The content is brief and serves primarily as a notification of the filing, without providing further details on the nature of the 8K report.
Advertisement

Perspective Therapeutics Reports Bamzireotide Trial Data, Targets Phase 2 Meeting in 1Q 2027

https://www.tradingview.com/news/tradingview:b39b90f2b3fe6:0-perspective-therapeutics-reports-bamzireotide-trial-data-targets-phase-2-meeting-in-1q-2027/
Perspective Therapeutics announced positive data from its Phase 1/2a bamzireotide trial, showing durable disease control and tumor responses in GEP-NET patients. The company reported 75% 18-month progression-free survival in SSTR2-positive GEP-NET patients, with high disease control and objective response rates in specific cohorts. Bamzireotide was well-tolerated, and the company plans an end-of-Phase 2 meeting in the first quarter of 2027.

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

https://www.globenewswire.com/news-release/2026/11/06/3397790/0/en/perspective-therapeutics-presents-promising-212pb-lapemelanotide-zapixetar-vmt01-monotherapy-data-from-a-phase-1-2a-study-in-heavily-pretreated-advanced-melanoma-patients-at-sitc-2.html
Perspective Therapeutics announced updated interim monotherapy results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at SITC 2026. The study showed meaningful antitumor activity, with a 75% disease control rate and durable disease stabilization at the 3.0 mCi dose, and no dose-limiting toxicities across 20 heavily pretreated patients. These positive safety and efficacy findings support further development of this targeted alpha therapy for patients with limited treatment options.

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

https://www.quantisnow.com/insight/perspective-therapeutics-presents-encouraging-incremental-data-and-analyses-from-phase-6777605
Perspective Therapeutics released additional Phase 1/2a trial data for bamzireotide, showing durable disease control and responses in gastroenteropancreatic NET patients with SSTR2-expressing target lesions. The drug remained well-tolerated, with the company targeting an end-of-Phase 2 meeting with regulators in Q1 2027 and Phase 3 initiation later that year, pending FDA feedback. Key figures include 75% progression-free survival at 18 months and response rates of 37% and 47% in Cohort 2 and 3 respectively.

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

https://www.globenewswire.com/news-release/2026/11/06/3397287/0/en/perspective-therapeutics-presents-encouraging-incremental-data-and-analyses-from-phase-1-2a-trial-of-212pb-bamzireotide-navoxetan-vmt-%CE%B1-net-in-advanced-sstr2-expressing-nets.html
Perspective Therapeutics announced encouraging incremental data and analyses from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with advanced SSTR2 expressing neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed durable disease control and robust responses, particularly in GEP-NET patients whose target lesions all express SSTR2+. The drug continues to be well-tolerated, and the company plans an end-of-Phase 2 meeting with the FDA in Q1 2027 to discuss a potential enrichment strategy for a Phase 3 study in 2027.

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $6

https://www.moomoo.com/news/post/1002656847/jonestrading-maintains-perspective-therapeutics-catxus-with-buy-rating-cuts-target
JonesTrading has reiterated its Buy rating for Perspective Therapeutics (CATX.US) but has adjusted its target price downwards to $6. This revision indicates a continued positive outlook on the company's prospects despite a lower price expectation.
Advertisement

Perspective Therapeutics’ [212Pb]VMT-α-NET shows responses in neuroendocrine tumor trial

https://www.clinicaltrialvanguard.com/news/perspective-therapeutics-212pbvmt-%CE%B1-net-shows-responses-in-neuroendocrine-tumor-trial/
Perspective Therapeutics reported positive interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET, an alpha-emitting radiopharmaceutical for neuroendocrine tumors, showing tumor responses in patients. These results, presented at the European Society for Medical Oncology Congress 2026, position VMT-α-NET within an active field of lead-212 therapies aiming to improve upon existing lutetium-177 treatments. While early-stage, the data are promising, but future disclosures will need to demonstrate durability of response.

RBC Capital Downgrades Perspective Therapeutics(CATX.US) to Hold Rating, Cuts Target Price to $4

https://www.moomoo.com/news/post/1002344221/rbc-capital-downgrades-perspective-therapeutics-catxus-to-hold-rating-cuts
RBC Capital has downgraded Perspective Therapeutics (CATX.US) from an Outperform to a Hold rating. Accompanying this downgrade, the firm also reduced its price target for the company's stock from $9 to $4. This adjustment reflects a more cautious outlook on the therapeutic company's prospects.

RBC Capital downgrades Perspective Therapeutics stock rating on trial data

https://www.investing.com/news/analyst-ratings/rbc-capital-downgrades-perspective-therapeutics-stock-rating-on-trial-data-93CH-4971803
RBC Capital has downgraded Perspective Therapeutics Inc. (NYSE: CATX) to Sector Perform from Outperform and reduced its price target from $14.00 to $4.00, following updated data from the company’s VMT-α-NET program. The downgrade is attributed to efficacy coming in "somewhat below expectations" and execution risks, despite the drug showing active nature and superior safety. The stock is currently trading near its 52-week low and has seen a significant plunge.

RBC Capital downgrades Perspective Therapeutics to Sector Perform, sets price target to $4

https://www.tradingview.com/news/tradingview:f2c2dd04f5ab5:0-rbc-capital-downgrades-perspective-therapeutics-to-sector-perform-sets-price-target-to-4/
RBC Capital has downgraded Perspective Therapeutics to Sector Perform, setting a price target of $4.00, which implies a 148.4% upside. The downgrade is primarily due to efficacy concerns regarding the VMT-α-NET program, where response rates declined, and execution risks, including a delayed Phase III trial and additional development challenges.

BTIG reiterates Buy on Perspective Therapeutics stock after data

https://www.investing.com/news/analyst-ratings/btig-reiterates-buy-on-perspective-therapeutics-stock-after-data-93CH-4971857
BTIG analyst Jeet Mukherjee has reiterated a Buy rating and $14.00 price target for Perspective Therapeutics Inc (NYSE:CATX) following the company's presentation of updated VMT-α-NET dataset at ESMO. Despite a recent sell-off attributed to a slight decrease in ORR in cohort 2 and two cases of acute kidney injury, BTIG believes the stock's reaction is excessive, noting the drug's superior efficacy compared to Lutathera and a favorable safety profile. Other analysts have offered mixed views, with some downgrading due to data and others initiating coverage with Outperform ratings, highlighting the company's lead-212 radiopharmaceutical platform.
Advertisement

RBC Downgrades Perspective Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $14, Keeps Speculative Risk

https://finance.yahoo.com/markets/stocks/articles/rbc-downgrades-perspective-therapeutics-sector-102839199.html
RBC has downgraded Perspective Therapeutics (CATX) from "Outperform" to "Sector Perform" and significantly reduced its price target from $14 to $4, while maintaining a "Speculative Risk" assessment. The article notes that Perspective Therapeutics currently holds an average analyst rating of "buy" with a mean price target of $11.31. The full content beyond the initial headline requires a Yahoo Finance Plus subscription.

BTIG reiterates Buy on Perspective Therapeutics stock after data By Investing.com

https://uk.investing.com/news/stock-market-news/btig-reiterates-buy-on-perspective-therapeutics-stock-after-data-93CH-4930789
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $14.00 price target on Perspective Therapeutics Inc (NYSE:CATX) following the presentation of new VMT-α-NET dataset at ESMO. Despite a recent stock sell-off, the analyst believes the market reaction is excessive given the drug's meaningful ORR compared to Lutathera and favorable safety profile. Other analysts have had mixed reactions, with RBC Capital downgrading the stock while William Blair and BMO Capital initiated coverage with Outperform ratings.

BTIG on Perspective Therapeutics Inc (CATX): 'would be buyers on weakness'

https://www.streetinsider.com/Analyst+Comments/BTIG+on+Perspective+Therapeutics+Inc+%28CATX%29%3A+would+be+buyers+on+weakness/27229828.html
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $14.00 price target for Perspective Therapeutics Inc (CATX) following the presentation of new VMT-α-NET data at ESMO. Despite a slight decrease in ORR for cohort 2 compared to prior updates and two cases of acute kidney injury, the analyst views the stock sell-off as overdone, citing VMT-α-NET's superior ORR and PFS rates compared to Lutathera, and a highly compelling benefit-risk profile. BTIG recommends buying on weakness, anticipating Phase 3 initiation in 2027.

Wedbush Adjusts Price Target on Perspective Therapeutics to $9 From $11, Keeps Outperform Rating

https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-perspective-090809653.html
Wedbush has lowered its price target for Perspective Therapeutics (CATX) from $11 to $9, while maintaining an Outperform rating on the stock. The article notes that Perspective Therapeutics, Inc. has an average analyst rating of "buy" and a mean price target of $12.08, indicating continued positive sentiment despite the adjustment.

Perspective Therapeutics reports interim trial results for NET cancer treatment

https://www.investing.com/news/company-news/perspective-therapeutics-reports-interim-trial-results-for-net-cancer-treatment-93CH-4969981
Perspective Therapeutics (NYSE AMERICAN:CATX) announced positive interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors, showing objective response rates of 33% and 50% in different cohorts. The trial reported high disease control rates and no serious adverse events, with the company planning for Phase 3 initiation in 2027. Investors can use InvestingPro to monitor the company's financial health as it progresses.
Advertisement

Perspective Therapeutics Reports VMT-α-NET Responses of 33% and 50% in Phase 1/2a Trial

https://www.tradingview.com/news/tradingview:5d348e281d810:0-perspective-therapeutics-reports-vmt-net-responses-of-33-and-50-in-phase-1-2a-trial/
Perspective Therapeutics reported positive interim results for its VMT-α-NET treatment in a Phase 1/2a trial, showing objective response rates of 33% and 50% in two dose cohorts, with 72% progression-free survival at 18 months across all cohorts. The company plans to initiate Phase 3 trials in 2027 following site preparations by year-end 2026. No significant toxicities or treatment discontinuations were observed.

Perspective Therapeutics Reports Encouraging ESMO Interim Data for [212Pb]VMT-α-NET in Neuroendocrine Tumors

https://www.quiverquant.com/news/Perspective+Therapeutics+Reports+Encouraging+ESMO+Interim+Data+for+%5B212Pb%5DVMT-%CE%B1-NET+in+Neuroendocrine+Tumors
Perspective Therapeutics, Inc. announced encouraging interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for patients with unresectable or metastatic neuroendocrine tumors (NETs) at the ESMO Congress 2026. The study showed a 72% progression-free survival rate at 18 months across cohorts and objective response rates of 33% in Cohort 2 and 50% in Cohort 3, with the treatment being well-tolerated and no dose-limiting toxicities. The company plans to complete Phase 3 preparations by year-end 2026, aiming to initiate the trial in 2027, indicating strong therapeutic potential for this targeted radiopharmaceutical.

Half of one group had tumor responses, including unconfirmed cases, in a cancer trial.

https://www.stocktitan.net/news/CATX/perspective-s-212pb-bamzireotide-navoxetan-vmt-net-demonstrates-hxptpk0koade.html
Perspective Therapeutics announced positive interim Phase 1/2a results for its VMT-α-NET treatment in advanced neuroendocrine tumors, showing objective response rates of 33% in Cohort 2 and 50% in Cohort 3, including unconfirmed responses. The treatment demonstrated durable disease control and a favorable safety profile with no dose-limiting toxicities. The company plans to initiate Phase 3 preparations by year-end 2026, with study initiation expected in 2027 following regulatory discussions with the FDA.

Form 8K Perspective Therapeutics Inc For: 23 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-perspective-therapeutics-inc-for-23-october-93CH-4900449
This article from Investing.com announces that Perspective Therapeutics Inc. filed a Form 8K on October 23. The brief notice highlights the filing for the company, identified by the stock symbol CATX, which experienced a significant drop.

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

https://sg.finance.yahoo.com/news/perspective-212pb-bamzireotide-navoxetan-vmt-144900244.html
Perspective Therapeutics announced positive interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for advanced SSTR2-expressing neuroendocrine tumors (NETs). The study showed encouraging safety, durable disease control (72% PFS at 18 months), and robust tumor responses (33% ORR in Cohort 2 and 50% in Cohort 3) across multiple dose cohorts. The company aims to complete Phase 3 site start-up preparations by year-end 2026, with Phase 3 initiation expected in 2027.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement